Costing methods in the Canadian literature on the economic evaluation of health care: A survey and assessment

International Journal of Technology Assessment in Health Care

Volumn 12, Issue 4, 1996, Pages 721-734

  Jacobs, Philip ^a   Bachynsky, John ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANADA; CLINICAL PRACTICE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE MANAGEMENT; HEALTH CARE COST; HEALTH SURVEY; METHODOLOGY; REVIEW; RISK ASSESSMENT; SOCIOECONOMICS;

EID: 0030451049     PISSN: 02664623     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0266462300011004     Document Type: Review

References (59)

1. Allen, U. D., Read, S., & Gafni, A. Zidovudine for chemoprophylaxis after occupational exposure to HIV-infected blood: An economic evaluation. Clinical Infectious Diseases, 1992, 14, 822-30.
2. Anderson, D. R., O'Brien, B. J., Levine, M. N., et al. Efficacy and cost of low-molecular-weight heparin compared with standard heparin for the prevention of deep vein thrombosis after total hip arthroplasty. Annals of Internal Medicine, 1993, 119, 1105-12.
3. Australia Commonwealth Department of Health, Housing, and Community Services. Manual of resource items and their associated costs. Canberra: Commonwealth Department, 1992.
4. Barrett, B. J., Parfrey, P. S., Foley, R. N., & Detsky, A. S. An economic analysis of strategies for the use of contrast media for diagnostic cardiac catheterization. Medical Decision Making, 1994, 14, 325-35.
5. Basken, T. F., & Parsons, M. L. Prevention of Rh(D) alloimmunization: A cost-benefit analysis. Canadian Medical Association Journal, 1990, 142, 337-39.
6. Boyle, M. H., Torrance, G. W., Sinclair, J. C., & Horwood, S. P. Economic evaluation of neonatal intensive care of very-low-birth-weight infants. New England Journal of Medicine, 1983, 308, 1330-37.
7. Canadian Coordinating Office for Health Technology Assessment. Guidelines for economic evaluation of pharmaceuticals: Canada. Ottawa: CCOHTA, 1994.
8. Caro, J. J., Trindade, E., & McGregor, M. The cost-effectiveness of replacing high-osmolality with low-osmolality contrast media. American Journal of Roentgenology, 1992, 159, 869-74.
9. Churchill, D. N., Lemon, B. C., & Torrance, G. W. A cost-effectiveness analysis of continuous ambulatory peritoneal dialysis and hospital hemodialysis. Medical Decision Making, 1984, 4, 489-500.
10. Coy, P., Schaafsma, J., Schofield, J. A., & Nield, J. A. Comparative costs of lung cancer management. Clinical and Investigative Medicine, 1994, 17, 577-87.
11. Detsky, A. S., & Jeejeebhoy, K. N. Cost-effectiveness of preoperative parenteral nutrition in patients undergoing major gastrointestinal surgery. Journal of Parenteral and Enteral Nutrition, 1984, 8, 632-37.
12. Donaldson, C. The state of the art of costing health care for economic evaluation. Community Health Studies, 1990, 14, 341-56.
13. Drummond, M. F., Stoddart, G. L., & Torrance, G. W. Methods for the economic evaluation of health care programs. Oxford: Oxford Medical Publications, 1987.
14. Eddy, R. J. Cost-effectiveness of CT scanning compared with mediastinoscopy in the preoperative staging of lung cancer. Canadian Association of Radiologists Journal, 1989, 40, 189-93.
15. Einarson, T. R., Arikian, S. R., & Shear, N. H. Cost-effectiveness analysis for onychomycosis therapy in Canada from a government perspective. British Journal of Dermatology, 1994, 130, S32-34.
16. Ellis, E., Koblin, W., Irvine, M. J., et al. Small, blue collar work site hypertension screening: A cost-effectiveness study. Journal of Occupational Medicine, 1994, 36, 346-55.
17. Estany, A., Todd, M., Vasquez, M., & McLaren, R. Early detection of genital chlamydial infection in women: An economic evaluation. Sexually Transmitted Diseases, 1989, 16, 21-27.
18. Evans, R. G., & Robinson, G. C. Surgical day care: Measurements of the economic payoff. Canadian Medical Association Journal, 1980, 123, 873-80.
19. Ferris, F. D., Wodinsky, H. B., Kerr, I. G., et al. A cost-minimization study of cancer patients requiring a narcotic infusion in hospital and at home. Journal of Clinical Epidemiology, 1991, 44, 313-27.
20. Fitzgerald, J. M., & Gafni, A. A cost-effectiveness analysis of the routine use of isoniazid prophylaxis in patients with a positive Mantoux skin test. American Review of Respiratory Disease, 1990, 142, 848-53.
21. Fulton, M. J., & Barer, M. L. Screening for congenital dislocation of the hip: An economic appraisal. Canadian Medical Association Journal, 1984, 130, 1149-56.
22. Gabriel, S. E., Jaakkimainen, R. L., & Bombardier, C. The cost-effectiveness of misoprostol for nonsteroidal antiinflammatory drug-associated adverse gastrointestinal events. Arthritis and Rheumatism, 1993, 36, 447-59.
23. Gerson, L. W., & Hughes, O. P. A comparative study of the economics of home care. International Journal of Health Services, 1976, 6, 543-55.
24. Goel, V., Deber, R. B., & Detsky, A. S. Nonionic contrast media: Economic analysis and health policy development. Canadian Medical Association Journal, 1989, 140, 389-95.
25. Goel, V., & Naylor, C. D. Potential cost effectiveness of intravenous tissue plasminogen activator versus streptokinase for acute myocardial infarction. Canadian Journal of Cardiology, 1992, 8, 31-38.
26. Goodwin, P. J., Feld, R., Evans, W. K., & Pater, J. Cost-effectiveness of cancer chemotherapy: An economic evaluation of a randomized trial in small-cell lung cancer. Journal of Clinical Oncology, 1988, 6, 1537-47.
27. Grizenko, N., & Papineau, D. A comparison of the cost-effectiveness of day treatment and residential treatment for children with severe behaviour problems. Canadian Journal of Psychiatry, 1992, 37, 393-400.
28. Gyldmark, M. A review of cost studies of intensive care units: Problems with the cost concept. Critical Care Medicine, 1995, 23, 964-72.
29. Hamilton, V. H., Racicot, F. E., Zowall, H., et al. The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease: Estimating the benefits of increasing HDL-C. Journal of the American Medical Association, 1995, 273, 1032-38.
30. Hull, R., Hirsh, J., Sackett, D. L., & Stoddart, G. Cost effectiveness of clinical diagnosis, venography, and noninvasive testing in patients with symptomatic deep-vein thrombosis. New England Journal of Medicine, 1981, 304, 1561-67.
31. Hull, R. D., Hirsh, J., Sackett, D. L., & Stoddart, G. L. Cost-effectiveness of primary and secondary prevention of fatal pulmonary embolism in high-risk surgical patients. Canadian Medical Association Journal, 1982, 127, 990-95.
32. Hull, R. D., Raskob, G. E., Hirsh, J., & Sackett, D. L. A cost-effectiveness analysis of alternative approaches for long-term treatment of proximal venous thrombosis. Journal of the American Medical Association, 1984, 252, 235-39.
33. Hutchison, B. G., & Stoddart, G. L. Cost-effectiveness of primary tetanus vaccination among elderly Canadians. Canadian Medical Association Journal, 1988, 139, 1143-51.
34. Jaakkimainen, L., Goodwin, P. J., Pater, J., et al. Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. Journal of Clinical Oncology, 1990, 8, 1301-09.
35. Jacobs, P., Henderson, I., & Nichols, D. Episodic acute care costs: Linking inpatient and home care. Canadian Journal of Public Health, 1995, 86, 200-05.
36. Kitai, I. C., King, S., & Gafni, A. An economic evaluation of varicella vaccine for pediatric liver and kidney transplant recipients. Clinical Infectious Diseases, 1993, 17, 441-47.
37. Krahn, M., & Detsky, A. S. Should Canada and the United States universally vaccinate infants against hepatitis B? A cost-effectiveness analysis. Medical Decision Making, 1993, 13, 4-20.
38. Kukull, W. A., Koepsell, T. D., Conrad, D., et al. Rapid estimation of hospitalization charges from a brief medical record review. Medical Care, 1986, 24, 961-66.
39. Labelle, R. J., Churchill, D. N., Martin, S., et al. Economic evaluation of extracorporeal shock wave lithotripsy, percutaneous ultrasonic lithotripsy, and standard surgical treatment of urolithiasis: A Canadian perspective. Clinical and Investigative Medicine, 1987, 10, 86-95.
40. Laupacis, A., Labelle, R., Goeree, R., & Cairns, J. The cost-effectiveness of routine post myocardial infarction exercise stress testing. Canadian Journal of Cardiology, 1990, 6, 157-63.
41. Levine, M. N., Drummond, M. F., & Labelle, R. J. Cost-effectiveness in the diagnosis and treatment of carcinoma of unknown primary origin. Canadian Medical Association Journal, 1985, 133, 977-87.
42. Logan, A. G., Milne, B. J., Achber, C., et al. Cost-effectiveness of a worksite hypertension treatment program. Hypertension, 1981, 3, 211-18.
43. Logan, A. G., Milne, B. J., Flanagan, P. T., & Haynes, R. B. Clinical effectiveness and cost-effectiveness of monitoring blood pressure of hypertensive employees at work. Hypertension, 1983, 5, 828-36.
44. McEwan, A. J. B., Amyotte, G. A., McGowan, D. G., et al. A retrospective analysis of the cost effectiveness of treatment with metastron in patients with prostate cancer metastatic to bone. European Urology, 1994, 26(Suppl. 1), 26-31.
45. Musto, R. J. Cost-effectiveness analysis of endocervical culture for N. gonorrhoeae at routine pelvic examination. Canadian Journal of Public Health, 1986, 77, 33-36.
46. O'Brien, B. J., Anderson, D. R., & Goeree, R. Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement. Canadian Medical Association Journal, 1994, 150, 1083-90.
47. Oldridge, N., Furlong, W., Feeny, D., et al. Economic evaluation of cardiac rehabilitation soon after acute myocardial infarction. American Journal of Cardiology, 1993, 72, 154-61.
48. Ontario Ministry of Health. Ontario guidelines for economic analysis of pharmaceutical products. Toronto: Ontario Ministry of Health, 1994.
49. Ostrowsky, J. T., Lippman, A., & Scriver, C. R. Cost-benefit analysis of a thalassemia disease prevention program. American Journal of Public Health, 1985, 75, 732-36.
50. Pineault, R., Contandriopoulos, A. P., Valois, M., et al. Randomized clinical trial of one-day surgery: Patient satisfaction, clinical outcomes, and costs. Medical Care, 1985, 23, 171-82.
51. Rajan, R., Gafni, A., Levine, M., et al. Very low-dose warfarin prophylaxis to prevent thromboembolism in women with metastatic breast cancer receiving chemotherapy: An economic evaluation. Journal of Clinical Oncology, 1995, 13, 41-46.
52. Scriver, C. R., Gregory, D., Bernstein, M., et al. Feasibility of chemical screening of urine for neuroblastoma case finding in infancy in Quebec. Canadian Medical Association Journal, 1987, 136, 952-56.
53. Sellors, J. W., Pickard, L., Gafni, A., et al. Effectiveness and efficiency of selective vs universal screening for chlamydial infection in sexually active young women. Archives of Internal Medicine, 1992, 152, 1837-44.
54. Sheingold, S., Churchill, D., Muirhead, N., et al. The impact of recombinant human erythropoietin on medical care costs for hemodialysis patients in Canada. Social Science and Medicine, 1992, 34, 983-91.
55. Tolley, K. & Glydmark, M. The treatment and care costs of people with HIV infections or AIDS: Development of a standardised cost framework for Europe. Health Policy, 1993, 24, 55-70.
56. Tousignant, P., Guttmann, R. D., & Hollomby, D. J. Transplantation and home hemodialysis: Their cost-effectiveness. Journal of Chronic Diseases, 1985, 38, 589-601.
57. Welch, H. G., & Larson, E. B. Rapid estimation of hospital charges in patients with leukemia. Medical Care, 1989, 27, 900-04.
58. Whynes, D. K. & Walker, A. R. On approximations in treatment costing. Health Economics, 1995, 4, 31-39.
59. Zowall, H., Fraser, R. D., Gilmore, N., et al. HIV antibody screening among immigrants: A cost-benefit analysis. Canadian Medical Association Journal, 1990, 143, 101-07.